Skip to content
Blerp – Lifestyle
Author:
Monte Rosa Therapeutics, Inc.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2026
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
September 1, 2026
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2026
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 8, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
April 20, 2026
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 17, 2026
1
2
Next Page
→